Sign in or create an account to add this stock to your watchlist.
About TearLab (OTCMKTS:TEAR)
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:TEAR
CUSIPN/A
Phone858-455-6006
Debt
Debt-to-Equity Ratio-1.33
Current Ratio1.52
Quick Ratio1.29
Price-To-Earnings
Trailing P/E Ratio-0.09
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$27.12 million
Price / Sales0.10
Cash FlowN/A
Price / CashN/A
Book Value($2.32) per share
Price / Book-0.11
Profitability
EPS (Most Recent Fiscal Year)($2.70)
Net Income$-16,100,000.00
Net Margins-46.77%
Return on EquityN/A
Return on Assets-74.58%
Miscellaneous
Employees42
Outstanding Shares10,440,000
TearLab (OTCMKTS:TEAR) Frequently Asked Questions
What is TearLab's stock symbol?
TearLab trades on the OTCMKTS under the ticker symbol "TEAR."
When did TearLab's stock split? How did TearLab's stock split work?
TearLab shares reverse split on Friday, February 24th 2017. The 1-10 reverse split was announced on Friday, February 24th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2017. An investor that had 100 shares of TearLab stock prior to the reverse split would have 10 shares after the split.
How were TearLab's earnings last quarter?
TearLab Corp (OTCMKTS:TEAR) issued its quarterly earnings results on Thursday, May, 10th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.37) by $0.28. The medical research company earned $6.45 million during the quarter. View TearLab's Earnings History.
When is TearLab's next earnings date?
What price target have analysts set for TEAR?
1 analysts have issued 1-year target prices for TearLab's stock. Their predictions range from $4.00 to $4.00. On average, they anticipate TearLab's share price to reach $4.00 in the next year. View Analyst Ratings for TearLab.
Who are some of TearLab's key competitors?
Some companies that are related to TearLab include Atossa Genetics (ATOS), Biostage (BSTG), Regenicin (RGIN), STRATA Skin Sciences (SSKN), Avinger (AVGR), Cytocore common stock (MDIT), Amedica (AMDA), Encision (ECIA), OxySure (OXYS), Delcath Systems (DCTHD), Calmare Therapeutics (CTTC), Viatar CTC Solutions (VRTT), AdvanSource Biomaterials Corpration Common Stock (ASNB), Lombard Medical Technologies (EVARF) and Quantrx Biomedical (QTXB).
Who are TearLab's key executives?
TearLab's management team includes the folowing people:
- Mr. Elias Vamvakas, Exec. Chairman & Sec. (Age 59)
- Mr. Joseph S. Jensen, Pres, CEO & Director (Age 46)
- Dr. Richard L. Lindstrom, Scientific Advisor & Independent Director (Age 70)
- Mr. Michael Marquez, Interim Chief Financial Officer (Age 36)
- Dr. Benjamin Sullivan Ph.D., Chief Scientific Officer (Age 42)
Has TearLab been receiving favorable news coverage?
Media stories about TEAR stock have trended somewhat positive recently, according to Accern. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TearLab earned a daily sentiment score of 0.13 on Accern's scale. They also assigned press coverage about the medical research company an impact score of 46.15 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of TearLab?
Shares of TEAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TearLab's stock price today?
One share of TEAR stock can currently be purchased for approximately $0.25.
How big of a company is TearLab?
TearLab has a market capitalization of $2.56 million and generates $27.12 million in revenue each year. The medical research company earns $-16,100,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis. TearLab employs 42 workers across the globe.
How can I contact TearLab?
TearLab's mailing address is 9980 Huennekens Street Suite 100, San Diego CA, 92121. The medical research company can be reached via phone at 858-455-6006 or via email at [email protected]
MarketBeat Community Rating for TearLab (TEAR)
MarketBeat's community ratings are surveys of what our community members think about TearLab and other stocks. Vote "Outperform" if you believe TEAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TEAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
TearLab (OTCMKTS:TEAR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for TearLab in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 1,500.00%. The high price target for TEAR is $4.00 and the low price target for TEAR is $4.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $5.75 | $5.75 |
| Price Target Upside: | 1,500.00% upside | 84.33% upside | 164.98% upside | 164.98% upside |
TearLab (OTCMKTS:TEAR) Consensus Price Target History
TearLab (OTCMKTS:TEAR) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
TearLab (OTCMKTS:TEAR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TearLab (OTCMKTS TEAR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.00%
Institutional Ownership Percentage: 0.17%
TearLab (OTCMKTS TEAR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/30/2017 | Awm Investment Company, Inc. | Major Shareholder | Sell | 327,674 | $3.20 | $1,048,556.80 | |  |
| 5/31/2016 | Brock Wright | Director | Buy | 59,686 | $0.78 | $46,555.08 | 808,378 | |
| 5/26/2016 | Brock Wright | Director | Buy | 130,314 | $0.76 | $99,038.64 | 719,732 | |
| 12/4/2014 | Elias Vamvakas | CEO | Buy | 50,000 | $2.24 | $112,000.00 | | |
| 11/18/2014 | Elias Vamvakas | CEO | Buy | 31,187 | $2.55 | $79,526.85 | | |
| 11/17/2014 | Elias Vamvakas | CEO | Buy | 18,813 | $2.55 | $47,973.15 | | |
| 11/11/2014 | Elias Vamvakas | CEO | Buy | 150,000 | $2.49 | $373,500.00 | | |
| 11/10/2014 | Elias Vamvakas | CEO | Buy | 16,276 | $2.50 | $40,690.00 | | |
| 11/10/2014 | Joseph Jensen | COO | Buy | 43,375 | $2.31 | $100,196.25 | | |
| 8/20/2014 | Brock Wright | Director | Buy | 23,000 | $3.82 | $87,860.00 | | |
| 8/19/2014 | Brock Wright | Director | Buy | 11,354 | $3.83 | $43,485.82 | | |
| 8/12/2014 | Elias Vamvakas | CEO | Buy | 70,000 | $3.43 | $240,100.00 | | |
| 6/30/2014 | Richard Lindstrom | Director | Sell | 5,000 | $4.61 | $23,050.00 | | |
| 5/13/2014 | Elias Vamvakas | CEO | Buy | 30,000 | $3.99 | $119,700.00 | 201,404 | |
| 5/13/2014 | Joseph Jensen | COO | Buy | 48,693 | $4.11 | $200,128.23 | 48,693 | |
| 4/1/2014 | Paul Karpecki | Director | Sell | 5,000 | $6.83 | $34,150.00 | 3,500 | |
| 1/2/2014 | Paul Karpecki | Director | Sell | 5,000 | $9.47 | $47,350.00 | 3,500 | |
| 12/31/2013 | Richard Lindstrom | Director | Sell | 5,000 | $9.26 | $46,300.00 | 86,238 | |
| 11/15/2013 | Richard Lindstrom | Director | Sell | 5,000 | $8.95 | $44,750.00 | 86,238 | |
| 10/11/2013 | Paul Karpecki | Director | Sell | 5,000 | $10.96 | $54,800.00 | 3,500 | |
| 9/3/2013 | William Dumencu | CFO | Sell | 7,000 | $13.22 | $92,540.00 | | |
| 8/1/2013 | William Dumencu | CFO | Sell | 7,000 | $14.39 | $100,730.00 | | |
| 7/1/2013 | Paul Karpecki | Director | Sell | 5,000 | $10.62 | $53,100.00 | | |
| 7/1/2013 | William Dumencu | CFO | Sell | 7,000 | $10.61 | $74,270.00 | | |
| 6/3/2013 | William Dumencu | CFO | Sell | 7,000 | $11.35 | $79,450.00 | | |
| 4/2/2013 | Tom Jr. Davidson | Director | Buy | 1,500 | $6.63 | $9,945.00 | | |
(Data available from 1/1/2013 forward)
TearLab (OTCMKTS TEAR) News Headlines
| Source: |
|
TearLab (OTCMKTS:TEAR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TearLab (OTCMKTS:TEAR) Income Statement, Balance Sheet and Cash Flow Statement
TearLab (OTCMKTS TEAR) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
